Bristol Myers Squibb Reports Positive COMMANDS Trial Results for Reblozyl in MDS

Bristol Myers Squibb today announced positive results from the Phase 3 COMMANDS trial evaluating Reblozyl (luspatercept-aamt) versus epoetin alfa in patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS). The trial met its primary endpoint, demonstrating that significantly more patients treated with Reblozyl achieved red blood cell transfusion independence for at least 12 weeks compared to epoetin alfa.